biogen eisai news - Search News

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi

Zacks.com on MSN · 1d

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending marketing approval for Leqembi (lecanemab) for early Alzheimer’s disease.

EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ago.

FiercePharma · 2d

EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | Upon reexamination, the EMA has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi.

1d

Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

1d

Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results